表紙
市場調査レポート

癌治療のためのチェックポイント阻害剤:2016〜2026年の市場予測 (CTLA-4およびPD-1阻害剤の可能性と研究開発)

Checkpoint Inhibitors for Treating Cancer - Market Report with Forecasts 2016-2026: Revealing Potentials of CTLA-4 and PD-1 Inhibitor Drugs and R&D

発行 Visiongain Ltd 商品コード 346762
出版日 ページ情報 英文 136 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=136.81円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
癌治療のためのチェックポイント阻害剤:2016〜2026年の市場予測 (CTLA-4およびPD-1阻害剤の可能性と研究開発) Checkpoint Inhibitors for Treating Cancer - Market Report with Forecasts 2016-2026: Revealing Potentials of CTLA-4 and PD-1 Inhibitor Drugs and R&D
出版日: 2015年12月11日 ページ情報: 英文 136 Pages
概要

レポートでは、癌治療のためのチェックポイント阻害剤市場について調査し、市場の概要と2026年までの市場発展予測、地域別動向、セグメント別予測、パイプライン動向などをまとめています。

第1章 レポートの概要

第2章 イントロダクション

第3章 主要なチェックポイント阻害剤:抗癌剤予測 (2016〜2026年) および主要企業

  • 2015年の主な抗癌剤治療
    • Yervoy
    • Opdivo
    • Keytruda
  • 主要企業
    • Bristol-Myers Squibbが市場を牽引

第4章 世界市場:2016〜2026年

  • 世界市場:2014年
  • 市場収益予測:2015〜2026年
  • 主なサブマーケット予測:2016〜2026年
    • CTLA-4
    • PD-1
    • 変わりゆく市場シェア
    • 促進因子と阻害因子

第5章 国別市場

  • 地域別動向
  • 地域別予測:2016〜2026年
  • 米国
  • EU
  • 日本
  • アジア太平洋地域

第6章 パイプライン分析

  • 抗PD-1阻害剤および抗PD-L1阻害剤
  • CTLA-4阻害剤
  • KIR阻害剤
  • 抗NKG2A阻害剤
  • VISTA阻害剤

第7章 市場定性分析

  • SWOT分析
  • 強みと弱み
  • 機会と脅威

第8章 調査インタビュー

第9章 結論

図表

目次
Product Code: PHA0082

Checkpoint Inhibitors for Cancer - Explore Sales Potentials of that Rising Market

Are you interested in the future of cancer drugs? Our new analysis forecasts revenues for checkpoint inhibitors. Visiongain's report gives those predictions to 2026 at overall world market, submarket, product and national level.

Avoid falling behind in data or losing influence. Instead discover what progress, opportunities and revenues those emerging cancer therapies can achieve. There you also explore trends, results, R&D and opportunities, seeing commercial prospects.

Read on, please, to explore the industry for checkpoint inhibitor cancer therapies and see what future revenue that expanding pharmaceuticals market could generate.

Predictions and other analysis to benefit your research, assessments, plans and decisions

The future looks promising for checkpoint inhibitors. New products enter that market and drug candidates reach clinical trials. Discover, from 2016, what revenues and other progress are possible in that emerging, expanding market.

Besides sales forecasting to 2026, our work shows recent results, growth rates and market shares. There you find original analysis. Also assess research and development. You gain 61 tables, 34 charts and two interviews with companies.

Our study's purpose is to help your research, analyses and decisions on cancer therapies using that emerging drug class. Our work also benefits your authority and reputation for commercial insight, helping you compete and succeed.

The following sections show how our new investigation benefits your work.

Forecasts covering the overall world market and segments for checkpoint inhibitors

Discover in our new analysis revenue predictions to 2026 for checkpoint inhibitor submarkets at overall world level, for cancer therapy, and by therapeutic class:

  • CTLA-4 Inhibitors
  • PD-1 Inhibitors
  • Products in development - the R&D pipeline.

Where lie the best prospects? You assess outlooks for revenue expansion, seeing where you can gain. You also investigate competitors' actions and outlooks.

That way you hear where needs and business opportunities exist. With a rising incidence of cancers, the demand for better treatment rises, giving pharma companies vast opportunities.

Discover what is possible. You also find sales forecasts by individual drug.

Predictions of products' sales - what is possible for those cancer-treating drugs?

How will checkpoint inhibitor medicines perform from 2015 to 2026 at world level? Our study forecasts revenues of these brands:

  • Yervoy (ipilimumab)
  • Opdivo (nivolumab)
  • Keytruda (pembrolizumab).

There you find how products can compete and succeed. That way you investigate trends, exploring challenges, changes and opportunities.

Discover what the future holds for checkpoint inhibitors and their developers, producers and marketers. Our work also shows you geographical sales predictions.

National markets - what outlooks for those anticancer drug revenues?

Advances in biopharma expand the range and use of checkpoint inhibitors. Our study shows you individual revenue forecasts to 2026 for seven national and two regional markets:

  • United States
  • Japan
  • Germany, France, United Kingdom, Italy and Spain (EU5)
  • European Union market overall
  • APAC region, grouped prediction

That way you assess countries and regions with highest revenues and potential sales growth. See what is possible in developed and developing countries.

Our study also explores developments for novel and improved cancer treatments.

R&D for those anticancer medicines - trends, innovations and progress

Our work assesses checkpoint inhibitor R&D in oncology. Profiles appear for 19 drug candidates, with revenue forecasts to 2026 for four agents:

  • Atezolizumab (MPDL3280A, Roche)
  • Durvalumab (MEDI4736, AstraZeneca/MedImmune)
  • Avelumab (MSB0010718C, Merck KGaA/Pfizer)
  • Tremelimumab (CP-675,206, AstraZeneca).

That way you examine technological advances, seeing progress in clinical trials.

Our report's author said: “We expect that market to continue its rise, changing cancer therapy. Those drugs have already made strides in melanoma and NSCLC (non-small cell lung cancer) treatment.

“Checkpoint inhibitors harness the body's immune system to attack cancerous cells, also using immune memory cells to eliminate relapses.”

Discover in our investigation what is possible. That R&D gains momentum from rising cancer prevalence and other forces raising demand for those emerging therapies.

Events and changes affecting companies treating cancer via checkpoint inhibitors

Explore other issues, including these forces shaping that industry and market:

  • Mechanisms and advantages of checkpoint inhibition
  • Pricing of treatments and effects of those costs on healthcare payers
  • Side effects and regulatory issues, including disadvantages of the therapies
  • Biomarkers paving the way for optimum utility
  • LAG-3 inhibitors - an emerging field of checkpoint inhibitor research
  • Combination therapies - their benefits and promise
  • Competition - see how crowded that market could become.

You also gain SWOT analysis, assessing what stimulates and restrains that expanding anti-cancer drugs market.

That way you see what is possible for leading pharma companies and specialists in biological drugs and related therapies. Why miss out? Instead explore what the future holds for checkpoint inhibitors in oncology.

Leading organisations and overall 2020 market value - what revenues are possible?

Our work predicts the world market for those drugs will reach $16.55bn in 2020. That market will multiply in revenues many times from 2016 to 2026. With our analysis you discover how high sales can go, seeing what is possible for those drug companies.

That way you assess what organisations hold most potential. Those companies include Bristol-Myers Squibb, Merck & Co., Roche, AstraZeneca and Pfizer.

Our study also shows you interviews with Innate Pharma and Prima Biomed. Discover what the future holds for participants in that industry, exploring what they say and do, as well as their potentials.

7 ways Checkpoint Inhibitors for Treating Cancer: Market Report with Forecasts 2016-2026 helps you

Our new investigation benefits your work in these seven main ways, helping you stay ahead in knowledge:

  • Revenues for anti-cancer checkpoint inhibitors to 2026 - assess scope for investments, developments, production and marketing
  • Submarket revenues to 2026 covering 3 therapeutic segments - explore treatment categories, seeing their sales outlooks from 2015
  • Existing and expected products' sales to 2026 - discover predicted revenues of 7 drugs, seeing how those medicines can compete and succeed
  • National market forecasting to 2026 for leading countries - explore the best regions for treatment demand, sales and revenue expansion
  • R&D - see progress, trends and prospects in that oncological research and development, finding technological, clinical and commercial possibilities
  • Companies, news and opinions - examine participants in that rising market, gaining insight to help you stay ahead, succeed and benefit your authority
  • Analysis of what stimulates and restrains that market - assess challenges and strengths, helping you compete and gain advantages.

That analysis, by our in-house team in the UK, gives knowledge to benefit your research, plans, decisions and proposals. It shows data you find nowhere else.

Gain predictions for checkpoint inhibitors, getting information to help you stay ahead

With our independent study you explore products, companies, progress and possibilities. Discover the best commercial opportunities, as well as ways to help cancer patients.

Having that information means you are less likely to fall behind in knowledge or miss opportunity. Through your choice now, find how to save time and effort, also benefiting your plans, decisions, presentations, proposals and influence.

Try that study. Our investigation shows data, trends, opportunities and forecasts for that expanding anti-cancer drugs market. So avoid missing out - please get our new report here now.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Overview of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2015
  • 1.2. Benefits of This Report
  • 1.3. How This Report Delivers
  • 1.4. Key Questions Answered by This Analytical Report
  • 1.5. Who is This Report For?
  • 1.6. Methods of the Study
  • 1.7. Frequently Asked Questions (FAQ)
  • 1.8. Associated Visiongain Reports
  • 1.9. About Visiongain

2. Introduction to the Checkpoint Inhibitor Anti-Cancer World Market 2015

  • 2.1. Checkpoint Inhibitors: A New Era in Immunotherapy
  • 2.2. Checkpoint Inhibitor Drug Treatments in Oncology

3. Leading Checkpoint Inhibitors: Anti-Cancer Drug Forecasts 2016-2026 and Leading Companies in the World Market

  • 3.1. Leading Checkpoint Inhibitor Anti-Cancer Drug Treatments on the Market in 2015
    • 3.1.1. Yervoy (ipilimumab) - Bristol-Myers Squibb
      • 3.1.1.1. Yervoy: Sales Analysis
    • 3.1.2. Opdivo (nivolumab) - Bristol-Myers Squibb/Ono Pharmaceutical
      • 3.1.2.1. Opdivo: Sales Analysis
    • 3.1.3. Keytruda (pembrolizumab) - Merck & Co.
      • 3.1.3.1. Keytruda: Sales Analysis
  • 3.2. Leading Companies in the Checkpoint Inhibitor Anti-Cancer Treatment Market in 2015
    • 3.2.1. Bristol-Myers Squibb Leads the Market

4. Checkpoint Inhibitor Anti-Cancer Treatment: World Market 2016-2026

  • 4.1. The Global Market for Checkpoint Inhibitor Anti-Cancer Treatments in 2014
  • 4.2. The World Anti-Cancer Checkpoint Inhibitor Market: Revenue Forecasts 2015-2026
  • 4.3. Leading Checkpoint Inhibitor Treatment Submarkets Forecast 2016-2026
    • 4.3.1. The CTLA-4 Inhibitors Submarket Forecast 2016-2026
    • 4.3.2. The PD-1 Inhibitors Submarket Forecast 2016-2026
    • 4.3.3. Changing Market Shares: PD-1 Inhibitors Will Lead the Market
    • 4.3.4. Drivers and Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2016-2026
      • 4.3.4.1. Drivers of the Checkpoint Inhibitor Anti-Cancer Treatment Market
      • 4.3.4.2. Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Market

5. Leading National Markets for the Checkpoint Inhibitor Anti-Cancer Treatment Market 2016-2026

  • 5.1. Regional Breakdown of the World Checkpoint Inhibitor Anti-Cancer Treatments Market 2014-2015
  • 5.2. World Checkpoint Inhibitor Anti-Cancer Treatment Market: Regional Forecast 2016-2026
    • 5.2.1. How Will Regional Market Shares Change to 2026?
  • 5.3. The US Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
  • 5.4. The EU Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
    • 5.4.1. Germany: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
    • 5.4.2. France: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
    • 5.4.3. Italy: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
    • 5.4.4. The UK: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
    • 5.4.5. Spain: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
  • 5.5. Japan: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
  • 5.6. The APAC Market: Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026

6. The Checkpoint Inhibitor Anti-Cancer Treatment Market Pipeline Analysis 2016-2026

  • 6.1. Anti-PD-1 Inhibitors and Anti-PD-L1 Inhibitors
    • 6.1.1. Atezolizumab (MPDL3280A/RG7446) - Roche/Genentech
    • 6.1.2. Durvalumab (MEDI4736) - AstraZeneca/MedImmune
    • 6.1.3. Avelumab - (MSB0010718C) - Merck KGaA/Pfizer
    • 6.1.4. Pidilizumab (CT-011) - CureTech Ltd
    • 6.1.5. AMP-224 - GSK/Amplimmune
    • 6.1.6. TSR-042 - TESARO Bio/AnaptysBio
    • 6.1.7. AMP-514 (MEDI0680) - AstraZeneca/MedImmune
    • 6.1.8. REGN2810 - Regeneron/Sanofi
  • 6.2. CTLA-4 Inhibitors
    • 6.2.1. Tremelimumab (CP-675,206) - AstraZeneca
  • 6.3. LAG-3 (lymphocyte activation gene-3) Inhibitors
    • 6.3.1. IMP321- Prima Biomed
    • 6.3.2. BMS-986016 - Bristol-Myers Squibb
    • 6.3.3. IMP701 - Prima BioMed/Novartis
  • 6.4. KIR Inhibitors
    • 6.4.1. Lirilumab (IPH2102/BMS-986015) - Innate Pharma/Bristol-Myers Squibb
  • 6.5. Anti-NKG2A Inhibitors
    • 6.5.1. IPH2201 - Innate Pharma/AstraZeneca/MedImmune
  • 6.6. Other Checkpoint Inhibitors
    • 6.6.1. VISTA Inhibitors
      • 6.6.1.1. CA-170 - Curis/Aurigene
    • 6.6.2. IDO and TDO Inhibitors
      • 6.6.2.1. Indoximod (NLG-9189) - NewLink Genetics
      • 6.6.2.2. NLG919 - NewLink Genetics
      • 6.6.2.3. INCB024360 - Incyte/Roche
    • 6.6.3. A2aR Inhibitors
      • 6.6.3.1. HTL-1071 - AstraZeneca/Heptares
    • 6.6.4. Future Areas of Pipeline Research

7. Qualitative Analysis of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2016-2026

  • 7.1. SWOT Analysis of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2016-2026
  • 7.2. Strengths and Weaknesses of the Checkpoint Inhibitor Anti-Cancer Treatment Market
    • 7.2.1. A Novel Treatment Method that Harnesses the Immune System's Vast Potential
    • 7.2.2. Pricing of the Treatments Will Attract Companies
    • 7.2.3. Cost of Treatment Will Restrain Market Access
    • 7.2.4. Side Effects May Prohibit Growth
  • 7.3. Opportunities and Threats for the Checkpoint Inhibitor Anti-Cancer Treatment Market
    • 7.3.1. Biomarkers Pave the Way for Optimum Utility
    • 7.3.2. Combination Therapies Are Achieving Superior Results
    • 7.3.3. The Cost Burden of Expensive Drug Treatments on Healthcare Systems
    • 7.3.4. Crowding of the Market With Similar Products

8. Research Interviews

  • 8.1. Interview with Dr Nicolai Wagtmann, PhD, Chief Scientific Officer, Innate Pharma, Marseille, France
    • 8.1.1. Innate Pharma's Immunotherapy Portfolio
    • 8.1.2. The Advantages and Mechanisms Used by Checkpoint Inhibitors
    • 8.1.3. The Disadvantages of Checkpoint Inhibitors
  • 8.2. Interview with Dr. Frédéric Triebel, CFO/CSO of Prima Biomed, Founder of Immutep
    • 8.2.1. LAG-3 Inhibitors: An Upcoming Area of Checkpoint Inhibitor Research
    • 8.2.2. Advantages and Disadvantages of LAG-3 Inhibitors on the Checkpoint Inhibitor Market
    • 8.2.3. The Future Direction of the Checkpoint Inhibitor Market for Prima Biomed

9. Conclusions

  • 9.1. The Global Checkpoint Inhibitor Anti-Cancer Treatment Market: Current World Outlook
    • 9.1.1. Driver for Growth: A Robust and Innovative Pipeline for the Checkpoint Inhibitors Anti-Cancer Treatment Market to 2026
  • 9.2. Leading National Markets for the Checkpoint Inhibitor Anti-Cancer Treatment Market 2016-2026: The US and EU Will Retain Their Lead
  • 9.3. The Future of the Checkpoint Inhibitor Anti-Cancer Treatment Market

List of Tables

  • Table 2.1: Main Types of Checkpoint Inhibitors in Development, 2015
  • Table 3.1: Yervoy (Ipilimumab): Historical Sales ($m, AGR%), 2011-2014
  • Table 3.2: Yervoy Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 3.3: Yervoy Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 3.4: Opdivo Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 3.5: Opdivo Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 3.6: Keytruda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 3.7: Keytruda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 3.8: Leading Companies in the Checkpoint Inhibitor Treatment Market: Revenue ($bn), Market Share (%), 2014
  • Table 3.9: Leading Companies in the Checkpoint Inhibitor Treatment Market: Revenue ($bn), Market Share (%), 2015
  • Table 4.1: Global Market for Anti-Cancer Checkpoint Inhibitors: Revenues ($bn) and Market Shares (%) by Class, 2014
  • Table 4.2: Checkpoint Inhibitors by Revenue ($bn), 2014
  • Table 4.3: Checkpoint Inhibitors by Revenue ($bn), 2015
  • Table 4.4: Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2015-2020
  • Table 4.5: Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2021-2026
  • Table 4.6: Global Market for Anti-Cancer Checkpoint Inhibitors: Revenues ($bn) and Market Shares (%) by Class, 2015
  • Table 4.7: Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2015-2020
  • Table 4.8: Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2021-2026
  • Table 4.9: Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2015-2020
  • Table 4.10: Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2021-2026
  • Table 4.11: Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Shares (%), 2015-2020
  • Table 4.12: Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Shares (%), 2021-2026
  • Table 4.13: Drivers and Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Market, 2015-2026
  • Table 5.1: Regional and National Breakdown of the Checkpoint Inhibitor Cancer Treatment Market: Market Sizes ($bn), Market Shares (%), 2014
  • Table 5.2: Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2015-2020
  • Table 5.3: Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2021-2026
  • Table 5.4: Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares (%), 2014-2019
  • Table 5.5: Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares (%), 2020-2026
  • Table 5.6: Forecast of the US Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 5.7: Forecast of the US Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 5.8: EU5 Market Shares (%), 2014-2019
  • Table 5.9: EU5 Market Shares (%), 2020-2026
  • Table 5.10: Forecast of the EU Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 5.11: Forecast of the EU Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 5.12: Forecast of the German Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 5.13: Forecast of the German Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 5.14: Forecast of the French Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 5.15: Forecast of the French Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 5.16: Forecast of the Italian Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 5.17: Forecast of the Italian Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 5.18: Forecast of the UK Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 5.19: Forecast of the UK Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 5.20: Forecast of the Spanish Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 5.21: Forecast of the Spanish Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 5.22: Forecast of the Japanese Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 5.23: Forecast of the Japanese Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 5.24: Forecast of the APAC Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 5.25: Forecast of the APAC Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 6.1: Selected Combination Therapies for Atezolizumab, 2015
  • Table 6.2: Atezolizumab Forecast: Revenue ($bn), 2016-2020
  • Table 6.3: Atezolizumab Forecast: Revenue ($bn), 2021-2026
  • Table 6.4: Durvalumab Forecast: Revenue ($bn), 2016-2020
  • Table 6.5: Durvalumab Forecast: Revenue ($bn), 2021-2026
  • Table 6.6: Avelumab Forecast: Revenue ($bn), 2017-2020
  • Table 6.7: Avelumab Forecast: Revenue ($bn), 2021-2026
  • Table 6.8: Tremelimumab Forecast: Revenue ($bn), 2016-2020
  • Table 6.9: Tremelimumab Forecast: Revenue ($bn), 2021-2026
  • Table 7.1: Strengths and Weaknesses of the Checkpoint Inhibitor Cancer Treatment Market, 2015
  • Table 7.2: Opportunities and Threats of the Checkpoint Inhibitor Cancer Treatment Market, 2015
  • Table 9.1: Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast by Region: Market Size ($bn), Market Share (%), CAGR (%), 2014, 2016, 2020, and 2026
  • Table 9.2: Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecasts by Class: Market Size ($bn), Market Share (%), CAGR (%), 2014, 2016, 2020, and 2026

List of Figures

  • Figure 1.1: Global Checkpoint Inhibitor Anti-Cancer Treatment Market Segmentation Overview, 2015
  • Figure 3.1: Yervoy (ipilimumab): Historical Sales ($m, AGR%), 2011-2014
  • Figure 3.2: Yervoy Forecast, Revenue ($bn), 2015-2026
  • Figure 3.3: Opdivo Forecast, Revenue ($bn), 2015-2026
  • Figure 3.4: Keytruda Forecast, Revenue ($bn), 2015-2026
  • Figure 3.5: Leading Companies in the Checkpoint Inhibitor Anti-Cancer Market by Revenue: Market Shares, 2014
  • Figure 3.6: Leading Companies in the Checkpoint Inhibitor Anti-Cancer Market by Revenue: Market Shares, 2015
  • Figure 4.1: Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class (%), 2014
  • Figure 4.2: Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Sizes ($bn), 2015-2026
  • Figure 4.3: Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class (%), 2015
  • Figure 4.4: Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), 2015-2026
  • Figure 4.5: Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), 2015-2026
  • Figure 4.6: Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class (%), 2020
  • Figure 4.7: Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class (%), 2026
  • Figure 5.1: Regional and National Breakdown of the Checkpoint Inhibitor Cancer Treatment Market: Market Shares (%), 2014
  • Figure 5.2: Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Sizes ($bn), 2014-2025
  • Figure 5.3: Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares (%), 2020
  • Figure 5.4: Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares (%), 2026
  • Figure 5.5: Forecast of the US Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
  • Figure 5.6: EU Market for the Checkpoint Inhibitor Cancer Treatment by Leading Country (%), 2014
  • Figure 5.7: Forecast of the EU Checkpoint Inhibitor Cancer Treatment Market, Market Sizes ($bn), 2014-2025
  • Figure 5.8: Forecast of the German Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
  • Figure 5.9: Forecast of the French Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
  • Figure 5.10: Forecast of the Italian Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
  • Figure 5.11: Forecast of the UK Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
  • Figure 5.12: Forecast of the Spanish Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
  • Figure 5.13: Forecast of the Japanese Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
  • Figure 5.14: Forecast of the APAC Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
  • Figure 6.1: Atezolizumab Forecast: Revenue ($bn), 2016-2026
  • Figure 6.2: Durvalumab Forecast: Revenue ($bn), 2016-2026
  • Figure 6.3: Avelumab Forecast: Revenue ($bn), 2017-2026
  • Figure 6.4: Tremelimumab Forecast: Revenue ($bn), 2016-2026
  • Figure 9.1: Checkpoint Inhibitor Anti-Cancer Drug Treatment Market Forecast by Class: Market Sizes ($bn), 2014, 2016, 2020, and 2026
  • Figure 9.2: Checkpoint Inhibitor Anti-Cancer Treatment Market Forecasts by Region: Market Size ($bn), 2014, 2016, 2020, and 2026

Companies Listed

  • AbbVie
  • Agilent Technologies
  • American Cancer Society
  • Amgen
  • Amplimmune
  • AnaptysBio
  • ASCO (American Society of Clinical Oncology)
  • AstraZeneca
  • Aurigene Discovery Technologies
  • Bristol-Myers Squibb
  • Celgene
  • CHMP (Committee for Medicinal Products for Human Use)
  • Commission de la Transparence
  • CoStim Pharmaceuticals
  • CRI (Cancer Research Institute)
  • CureTech Ltd
  • Curis Inc
  • Daiichi Sankyo
  • Dako (subsidiary of Agilent Technologies)
  • DMC (Data Monitoring Committee)
  • DNAtrix
  • Dynavax
  • Eddingpharm
  • EMA (European Medicines Agency)
  • European Organisation for Research and Treatment and Cancer (EORTC)
  • FDA (US Food and Drug Administration)
  • French National Authority for Health
  • GlaxoSmithKline (GSK)
  • Heptares
  • IGR (Institut Gustav Roussy)
  • Immutep
  • Incyte
  • Innate Pharma
  • INSERM
  • iTeos Therapeutics
  • J&J
  • LICR (Ludwig Cancer Research)
  • Medarex
  • MedImmune
  • Medivation Inc
  • Merck & Co.
  • Merck KGaA
  • MHLW (Ministry of Health, Labour, and Welfare)
  • MHRA (Medicines and Healthcare Products Regulatory Agency)
  • Mirati Therapeutics
  • NEC Corporation
  • NewLink Genetics
  • NHS (National Health Service)
  • NICE (the National Institute for Health and Care Excellence)
  • Novartis
  • Novo Nordisk
  • Ono Pharmaceutical
  • Paris University
  • Pfizer
  • Pharmacyclics
  • Plexxikon (subsidiary of Daiichi Sankyo)
  • Prima Biomed
  • QIMR Berghofer Medical Research Institute
  • Regeneron
  • Roche
  • Sanofi
  • Sosei Group Corporation
  • Syndax
  • TESARO Inc
  • Teva Pharmaceutical Industries
  • The de Duve Institute
  • WHO (World Health Organization)
  • Yamaguchi University
Back to Top